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Abstract 
 
The purpose of this study was to design poly(lactide-co-glycolide) (PLGA) 
microspheres for the continuous delivery of the somatostatin analogue vapreotide 
over 2-4 weeks. The microspheres were produced by spray-drying and the desired 
characteristics, i.e. high encapsulation efficiency and controlled release over 2-4 
weeks, achieved through optimizing the type of polymer, processing solvent and co-
encapsulated additive. The in vitro release was tested in fetal bovine serum 
preserved with 0.02% of thiomersal. Furthermore, formulations were injected 
intramuscularly into rats to obtain pharmacokinetic profiles. Encapsulation efficiency 
was between 34 and 91%, depending on the particular formulation. The initial  
peptide release (within 6 h) was lowest, i.e. <20%, when acetic acid was used as 
processing solvent and highest, i.e. 57%, with dichloromethane. The various co-
encapsulated additives generally lowered the encapsulation efficiency by 15-30%. 
The best formulation in terms of low burst and effective drug serum levels (> 1 ng/ml) 
over 21 to 28 days in rats was the one made with end-group uncapped PLGA 50:50, 
the solvent acetic acid and the additive polyethyleneglycol. In conclusion, the 
optimization of formulation parameters allowed us to produce vapreotide-loaded 
PLGA microspheres of suitable characteristics for therapeutic use. 
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1. Introduction 
The medical application of peptides is subject to a number of well-known 
problems such as limited stability in pharmaceutical formulations or enzymatic 
degradation and, hence, low bioavailability. Drug delivery systems are generally  
considered very useful to overcome these difficulties [1]. One way to obtain 
therapeutic drug levels is by encapsulating peptides into bioerodable polymer 
microspheres that protect the peptides against inactivation and prolong their release 
over a few weeks. Furthermore, controlled release parenteral dosage forms may 
improve the efficacy of drugs by reducing the frequency of injections and by 
decreasing plasma level fluctuations [2]. Vapreotide, (RC-160, DFCYDWKVCW-NH2), 
an analogue of somatostatin, synthesized by Cai et al. [3], has been experimentally 
shown to be particularly active in various proliferation conditions, e.g., breast and 
prostate cancers; vapreotide has been successfully used in man, amongst others, 
against AIDS-related diarrhea [4, 5]. Vapreotide is a typical representative of 
biologically active peptide drugs with high therapeutic potential, but a relatively short 
plasma half-life after parenteral administration. Despite the variety of therapeutic 
activities, vapreotide has only limited clinical usefulness because of the necessity of 
continuous intravenous infusion. Indeed, a simple parenteral administration of this 
peptide may not be fully effective, and frequent injections or continuous infusion are 
required to ensure adequate plasma levels. Therefore, to obtain a long-term and 
constant therapeutic effect, a sustained release system is needed.  
Microparticulate controlled-release systems, prepared from poly(lactide) 
(PLA) or poly(lactide-co-glycolide) (PLGA), have been widely investigated for the 
delivery of drugs [6, 7]. PLA/PLGA microparticles appear particularly promising as 
delivery systems for proteins [8, 9] or peptides [10, 11]. According to previous  
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studies the release of a molecule from PLG/PLGA microspheres may depend on the 
polymer (lactic/glycolic acid ratio, molecular weight) [12, 13] and microsphere (size, 
loading) characteristics [14, 15]. Comparatively little data are available on the effect 
of co-encapsulated additives on drug release from PLA/PLGA microspheres. 
In the present study, several additives were co-encapsulated together with 
the peptide vapreotide to develop a formulation that delivers this peptide drug in a 
continuous manner over a period of three weeks to one month. The vapreotide 
loaded PLA/PLGA microspheres were characterized in terms of size, morphology, in 
vitro peptide release and drug plasma levels in rats.  
 
2. Materials and methods 
2.1 Materials 
Poly(d,l-lactide) (PLA) and various poly(d,l-lactide-co-glycolide) (PLGA) 
differing in molecular weight and composition were purchased from Boehringer 
Ingelheim (Ingelheim, Germany). They included end-group capped and uncapped 
PLGA 50:50 (Resomer® 502; Mw of approx. 14 kDa), end-group capped PLGA 75:25 
(Resomer® 752; Mw of approx. 17 kDa ) and PLA (Resomer® R202; Mw of approx. 
14kDa). The somatostatin analogue vapreotide pamoate, (DFCYDWKVCW-NH2), was 
synthesized by Novabiochem, Laufingen, Switzerland. Chitosan (SEA CURE CL 210) 
was a gift from Pronova Biopolymer (Lysaker, Norway). Bovine serum albumin 
(BSA), polyethyleneglycols (PEG 10000, PEG 20000), ethyl stearate, and the 
analytical grade ethyl formate (EF) and dichloromethane (DCM) were from Fluka 
(Buchs, Switzerland). Acetic acid was from Merck (Dietikon, Switzerland) and fetal 
bovine serum from Gibco BRL (Basel, Switzerland). 
2.2  Microencapsulation 
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Vapreotide microspheres were prepared by spray-drying. The peptide was 
either dissolved in a 5% (w/w) polymer solution in acetic acid or dispersed, by means 
of magnetic stirring, in a 5% (w/w) polymer solution in DCM or EF. The suspension, 
containing the polymer and drug, was spray-dried in a laboratory spray-dryer (Mini 
Spray-Dryer 190, Büchi, CH-Flawil) with the following process parameters: product 
feed: 3 ml/min; inlet temperature: 50 °C; outlet temperature: 40 °C; aspirator setting: 
40 m3/h; spray-flow: 450 Nl/h. A 0.7 mm nozzle was used throughout the 
experiments. The following additives were individually co-encapsulated: BSA, PEG 
6000, PEG 10000, PEG 20000, chitosan and ethyl stearate. The additives were 
dissolved or dispersed, by magnetic stirring, in the polymer solution. 
The obtained microspheres were further processed following a previously 
established protocol [8]. Briefly, the particles were washed with a 0.1% (w/w) 
poloxamer 188 solution and distilled water, and collected on a 0.2 μm cellulose 
acetate filter. After drying under vacuum (10 mbar) at room temperature for 24 hours, 
the microspheres were redispersed in hexane to break up any aggregated particles, 
and dried again under vacuum (10 mbar) for 12 hours. This protocol was found 
suitable to eliminate efficiently residual amounts of water and organic solvents from 
the microspheres. Typical ranges of residual organic solvents in the particles were 
below 200 ppm (unpublished data). The product yield generally lay in the range of 70 
to 78% with respect to the amount of starting solid materials. 
2.3  HPLC-method for peptide assay 
The intact peptide was analyzed by HPLC (Column Licrospher® RP-18, 4 x 
250 mm, Merck, Darmstadt, Germany). The elution phase consisted of a gradient of 
A (triethylammonium phosphate buffer of pH 2.3; TEAP) and B (acetonitrile/TEAP pH 
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2.3, 60/40), with B increasing from 30 to 80% (v/v) within 25 min. Detection was at 
215 nm. 
2.4  Morphology, size and calorimetric transitions of microspheres  
For morphological examination, the microspheres were mounted on double-
face adhesive tape, sputtered with platinum and viewed in a Hitachi S-700 scanning 
electron microscope (SEM). 
Size and size distribution of the microspheres were analyzed by light 
microscopy (Wild, Heerbrugg, Switzerland) and laser light diffraction (Mastersizer®, 
Malvern, UK). 
Calorimetric transitions of the native drug and microspheres loaded with the 
drug were determined by differential scanning calorimetry (DSC-7, Perkin Elmer, 
Hünenberg, Switzerland). The temperature range was from 20 to 230 °C, and the 
samples heated at a rate of 10 °C/min. 
2.5   Determination of vapreotide content in the microspheres 
The vapreotide content in the PLGA microspheres was determined by HPLC 
according to a method described previously [16]. The peptide loaded microspheres 
were dissolved in 3 ml of acetonitrile, to which 2 ml of chloroform were added, and 
the mixture was stirred vigorously. The peptide was extracted three times with 2 ml of 
triethylamino phosphate buffer of pH 2.3. The entrapment efficiency of vapreotide 
was calculated as the ratio of actually measured to theoretical (nominal) drug content 
in the microspheres. 
2.6  NMR study 
To verify that vapreotide pamoate was not modified chemically by the 
exposure to acetic acid during microencapsulation, we have used analytical one- and 
two-dimensional NMR spectroscopy. During the study 1D proton spectra of 
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vapreotide pamoate where compared to spectra recorded on vapreotide pamoate 
that had been pre-treated with acetic acid. For the latter sample, 10 mg of the peptide 
salt were dissolved in 500 μl of acetic acid, the solvent was evaporated under 
vacuum (Speed Vac 110, Savant Instruments, Farmingdale, NY, U.S.A.), and the 
pellet was re-suspended in 500 μl of deuterated dimethylsulfoxide (d6-DMSO). 
Furthermore, 10 mg of vapreotide pamoate and 10 mg of vapreotide acetate were 
separately dissolved in 500 μl of d6-DMSO. In addition, [13C,1H] correlation 
experiments were recorded for both the original and the acid pre-treated vapreotide 
pamoate. 
2.7  In vitro release 
In vitro drug release profiles (up to 28 days) were obtained by incubating the 
microspheres (approx. 10 mg accurately weighed, n=3) in 4.0 ml of fetal bovine 
serum preserved with 0.02% (w/w) of thiomersal. Incubation took place in rotating 
vials at 37 °C. The amount of drug released was determined indirectly by measuring 
the amount of drug remaining in the microspheres. Indeed, a previous investigation 
has shown that vapreotide remained intact inside microspheres upon incubation in 
serum, but degraded substantially, i.e. 85% within 14 days, once released from the 
microspheres [16]. At given time intervals, three vials for each microsphere 
formulation were withdrawn, and the polymer particles were separated by 
centrifugation. After removing the supernatant, the polymer mass was dried overnight 
at 10 mbar and room temperature. The amount of remaining vapreotide in the 
microspheres was determined by HPLC, as described above. The peptide extracted 
from the incubated microspheres was intact, as no degradation products were 
detected in the extraction solution with the sensitive HPLC-method used [16]. 
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2.8  In vivo study 
In vivo evaluation of selected formulations (4 types of microspheres) was 
performed in male Sprague-Dawley rats (weighing 380-400 g, from C.E.R.J., Les 
Genest St. Isle, France). The animals were maintained under constant environmental 
conditions (22  1°C; 50  5% rel. humidity). Food and water were available ad 
libitum. Microspheres were suspended in an injection vehicle (the dose of peptide per 
rat was 1.5 mg, calculated as vapreotide base) and administered intramuscularly. 
Blood samples were collected at different time intervals for 28 days. Vapreotide 
concentrations in the blood samples were determined by radio-immuno assay [17] 
with a sensitivity of 50 pg/ml. Data were presented as mean ± standard deviation. 
Statistical comparisons were made using Student’s t-test, and a P-value lower than 
0.05 was considered significant. Correlation between in vitro and in vivo data was not 
entirely satisfactory and requires further clarification before it may be presented. 
 
3. Results and discussion 
3.1 Morphology, drug content and burst release  
The size of the microspheres lay within a relatively narrow range of 1-15 μm. 
No significant size differences were detectable amongst all the preparations. 
Representative SEM micrographs of the particles show that the shape of the 
microspheres was affected by the processing solvent and by the co-encapsulation of 
additives (Fig. 1). The end-group uncapped PLGA 50:50 microspheres prepared with 
ethyl formate (Fig. 1A) or acetic acid (Fig. 1C) were spherical and showed no  
aggregation. In contrast, the microspheres prepared with DCM (Fig. 1B) or with 
acetic acid and co-encapsulated PEG 20000 (Fig. 1D) had an irregular shape and 
were aggregated. A similar morphology was seen with end-group capped PLGA 
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50:50 microspheres containing PEG 20000 (results not shown). These results 
indicate that both the solvent dichloromethane and the additive PEG 20000 exerted, 
at least before the final drying of the particles, a plasticizing effect on the 
microspheres.  
Tables 1 and 2 summarize the drug loading and burst release from the 
microspheres prepared with various polymers, solvents and additives. The highest 
entrapment efficiency of 91% was achieved with ethyl formate as processing solvent, 
while only 65-67% efficiency was achieved with dichloromethane and acetic acid 
(Table 1). This difference of entrapment efficiency cannot, at present, be explained. 
In contrast to the very satisfactory drug entrapment with ethyl formate, the burst 
release of drug from the microspheres made with this solvent was rather high, i.e. 44 
and 55 % after 1 and 6 h, respectively. In view of a therapeutic use, the microspheres 
prepared from acetic acid gave a more appropriate burst release, i.e., 11 and 18% 
after 1 and 6 h, respectively. The higher burst release from the microspheres 
prepared with ethyl formate or dichoromethane may be explained by the different 
solubility of the peptide in these solvents. In acetic acid, the peptide had a solubility of 
> 40 mg/ml, whereas in ethyl formate and dichoromethane the peptide was only 
slightly soluble (5.3 and 4.5 mg/ml, respectively). For microencapsulation, the peptide 
had to be suspended in the polymer solutions made with the latter two solvents, 
whereas it could be dissolved in the acetic acid polymer solution. Thus, the low initial 
burst release observed when using acetic acid probably indicates a homogenous 
drug distribution resulting in only minor amounts of peptide located at the particle 
surface. In any case, the glass transition temperature of the microspheres was 
comparable between the various preparations and lay between 45 and 50 °C (data 
not shown). DSC thermograms further suggested formation of a solid solution 
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between the peptide salt and the PLGA 50:50 microspheres, as endo- and 
exothermic transitions of the native drug compound (between 130 and 170 °C) were 
not detectable with the micrsopheres loaded with the drug. Finally, pharmacokinetic 
experiments in rats revealed a very good agreement between Cmax and the amount of 
burst release in vitro (data not shown). Therefore, acetic acid was used as 
processing solvent for all further microsphere formulations. 
With the aim to improve the encapsulation efficiency while maintaining the 
low burst release, various formulation parameters were varied: (i) nominal drug 
loadings were varied between 5 and 30%; (ii) various additives were co-
encapsulated; (iii) end-group capped PLGA 50:50, PLGA 75:25 and PLA were used 
(Table 2). Increasing the nominal drug loading from 5 to 20% lowered the 
encapsulation efficiency from 70 to 54%. This is a well described phenomenon [10] 
that can be related to a higher osmotic pressure of highly loaded matrices and larger 
pores formed at higher loadings. The addition of additives generally lowered the 
encapsulation efficiency from 65% (10% nominal loading) to values between 34 
(ethyl stearate), 38 (BSA), 40 (chitosan), and 40 to 50% (PEGs) (Table 2). Increasing 
the nominal amount of PEG 20000 from 10 to 30% also lowered slightly the 
encapsulation efficiency. The effect of the additives might be ascribed to an increase 
of porosity of the microspheres. Our rationale for using these additives lay mainly in a 
potential enhancement of polymeric entanglement (PEG, BSA) and hydrophobicity 
(ethyl stearate) inside the microspheres and in a ionic interaction (chitosan) with the 
peptide drug. However, the assumed effects did not occur. Finally, the end-group 
capped PLGA 50:50, PLGA 75:25 and PLA did not improve the microencapsulation 
efficiency.  
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Drug release within the first 6 h (also called burst release) was between 10 
and 20% of the actual loading, irrespective of nominal loading (5, 10, 20% in end-
group uncapped PLGA 50:50)  and polymer type (end-group capped PLGA 75:25, 
PLA). Similarly, the co-encapsulated additives BSA, chitosan and ethyl stearate had 
no significant effect on the burst release. By contrast, co-encapsulated PEGs 
significantly (P < 0.05) increased the burst release as compared to the additive-free 
microspheres. This might be due to the plasticizing effect of this type of additive, as 
suggested above, or to an increase of hydrophilicity of the microspheres that contain 
PEGs.  
3.2 NMR study 
The results from one-dimensional NMR clearly proved that no chemical 
modification of vapreotide pamoate occurred upon treatment with acetic acid. This is 
evident from the very high similarity between the 1D spectra of the reference and test 
samples. However, two signals had different line-shapes in the 1D spectra of the two 
samples. We suspect this to be due to the more acidic pH in the sample treated with 
acetic acid. Such a pH-shift alters the exchange rate of labile protons, e.g. hydroxyl 
or amide protons, with the water that is contained in the sample and hence alters the 
line-width. We have confirmed this mechanism by supplementing our data with 
proton, carbon 2D correlation experiments. The experiments gave virtually identical 
correlation maps for the two forms, a result that is impossible if the sample would 
have undergone chemical modifications during the acid treatment. Finally, the 
absence of chemical modifications by acetic acid treatment was also confirmed by 
mass spectroscopic measurements (results not shown). 
3.3 In vitro release kinetics 
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In a previous study [16], the in vitro release of vapreotide pamoate from 
microspheres has been shown to depend greatly on the type of release medium. 
Serum was found to be the most appropriate medium that produced the best 
agreement with in vivo data. For this reason, serum preserved with 0.02% of 
thiomersal, was used here again as release medium.  
Figure 2 depicts the in vitro release profiles of vapreotide from microspheres 
made of end-group uncapped PLGA 50:50 (RG502H) and end-group capped PLGA 
75:25 (RG752) and PLA (R202) with nominal drug loadings of 10%. The PLGA 
microparticles released the peptide considerably faster (88 and 73% in 28 days from 
PLGA 50:50 and PLGA 75:25, respectively) than the PLA microparticles (24% in 28 
days). These observations agree with results published by others [14, 18, 19]. All the 
profiles showed a modest burst release of 12 - 18%. In contrast to comparable 
studies, the present release profiles did not exhibit a pronounced triphasic pattern 
(burst release - dormant period - second release pulse). Further, the minor effect of 
nominal drug loading (5, 10 and 20%) on the release kinetics is shown in the inset. 
This suggests a strong interaction between polymer and drug within this loading 
range. Nonetheless, the slightly increased burst release from the formulation 
containing nominally 20% drug agrees with results reported by others [20-22]. 
The co-encapsulation of additives into end-group uncapped PLGA 50:50 
microspheres exerted slight effects on the overall release pattern, but not on the 
duration of release. (Fig. 3). After the burst (discussed above), the release rate was 
generally lowered when the formulations contained additives. A rather continuous 
release pattern was observed with the microspheres without additive and those 
containing PEG 20000. This agrees with release studies of timolol maleate from 
PLGA 50:50 microspheres containing PEG 6000 [23]. With the additives BSA, 
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chitosan and ethyl stearate, the profiles became more triphasic, which was most 
pronounced with the latter two excipients. It has been speculated that the dormant 
phase of triphasic peptide release profiles might be due to ionic interaction between 
the anionic polymer chains and peptides, or to collapse of the microporous structure 
inside the microspheres upon water penetration and polymer swelling [10]. Whether 
either of these mechanisms play a role in the here presented release remains 
unknown. Similarly, the discontinuous in vitro release of EPO from PLGA 50:50 
microspheres was not significantly modified by the various additives used in the study 
by Morlock et al. [24]. 
3.4 In vivo study 
For the pharmacokinetic study in rats, end-group uncapped PLGA 50:50 
microspheres (10% nominal loading, with and without co-encapsulated PEG 20000; 
20% nominal loading, no additive) and end-group capped PLA microspheres (10% 
nominal loading, no additive) were selected (Table 2). Each formulation was injected 
i.m. into rats, and vapreotide serum concentrations monitored for 28 days (Fig. 4). 
With the exception of the PLA microspheres, all the other formulations produced  
drug levels higher than 1 ng/ml for up to at least three weeks. The most prolonged 
plasma levels appeared with the PLGA 50:50 microspheres with 10% nominal drug 
loading and co-encapsulated PEG 20000. However, after day 6, the differences in 
the profiles obtained with all three PLGA 50:50 formulations were statistically not 
significant (P > 0.05). By contrast, PLA microspheres produced detectable serum 
levels for two days only. These in vivo results agree qualitatively quite well with the in 
vitro release profiles (Figs. 2 and 3). Indeed, with the PLGA 50:50 formulations, 
relatively continuous in vitro release was observed over approx. 28 days, whereas 
with the PLA particles, only very minor amounts of peptide were released after the 
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initial 6 h (Figs. 2 and 3). Further erosion controlled release was not likely to occur as 
this homopolymer degrades relatively slowly [8].  
Previous experiments with microspheres prepared with dichoromethane or 
ethyl formate produced very high Cmax-values (105-135 ng/ml), and plasma levels 
were maintained over 7-10 days only [16]. Conversely, all microspheres formulations 
prepared with acetic acid yielded moderate Cmax-values from 38 to 54 ng/ml one hour 
after injection (Fig. 4). We may speculate that the very modest burst release in vitro 
and in vivo may be ascribed to relatively low amounts of drug located at the surface 
of the particles. Since acetic acid is a good solvent for both the peptide and the 
polymer, a homogeneous drug distribution inside the microspheres can be expected.  
Another advantage of the processing solvent acetic acid resides in the good 
safety profile of this solvent. Acetic acid is indeed listed as class 3 solvent in the ICH 
guidelines [25]. Thus, residual acetic acid in the microspheres, which remains to be 
determined, should not give rise to safety concerns. 
 
4. Conclusions 
The objective of this work was to design degradable microspheres for 
delivering vapreotide at significant plasma levels over 3-4 weeks. In this work, we: (1) 
successfully encapsulated vapreotide pamoate in PLA/PLGA microspheres using a 
spray-drying method, (2) demonstrated that the in vitro and in vivo release of the 
peptide depended on the type of polymer, solvent and additive used, and (3) 
achieved significant drug levels in rats over three weeks after intramuscular 
administration.  
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Figure legends 
 
Figure 1. Scanning electron micrographs of spray-dried end-group uncapped PLGA 
50:50 microparticles. Effect of processing solvent and additive: ethyl formate (a); 
dichloromethane (b); acetic acid (c); acetic acid, PEG 20000 (d). The horizontal 
dimension of the micrographs corresponds to 46 μm. 
 
Figure 2. In vitro release of vapreotide pamoate from PLA and PLGA microspheres in 
serum, containing 0.02% of thiomersal. Effect of polymer type: end-group uncapped 
PLGA 50:50 (?); end-group capped PLGA 75:25 (n); end-group capped PLA (s). 
Inset: Release profiles of uncapped PLGA 50:50 microspheres loaded with nominal 5 
(?), 10 (×) and 20% (n) of drug.  
 
Figure 3. In vitro release of vapreotide pamoate (10%, w/w, nominal loading) from 
end-group uncapped  PLGA 50:50 microspheres in serum, containing 0.02% of 
thiomersal. Effect of the presence of co-encapsulated additives (generally 10%, 
except for ethyl stearate (5%, w/w), with respect to PLGA mass): Chitosan (×), ethyl 
stearate (?), PEG 20000 (?) and BSA (?). For comparison, vapreotide release from 
microspheres without additive is given in Fig. 2. 
 
Figure 4. Plasma levels of vapreotide levels in rats after intramuscular injection of 1.5 
mg peptide (base equivalent) contained in various microsphere formulations: end-
group uncapped PLGA 50:50, 10% nominal loading, no additive (?); end-group 
uncapped PLGA 50:50, 20% nominal loading, no additive (?); end-group uncapped 
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PLGA 50:50, 10% nominal loading, PEG 20000 (?); end-group capped PLA, 10% 
nominal loading, no additive (×).  
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Table 1: Effect of the processing solvent used on the entrapment efficiency (E.E.) 
and burst release of vapreotide pamoate from end-group uncapped PLGA 50:50 
microspheres. The nominal drug loading was 10%, relative to the microsphere mass. 
 
Solvent E. E. 
 
(%) 
 Peptide released after 
 1h 6h 
(%) 
Ethyl formate 91 ± 1 44 ± 1.0 55 ±   0.5 
Dichloromethane 67 ± 4 57 ± 0.8 64 ± 10.0 
Acetic acid 65 ± 5 11 ± 1.5 18 ±   0.9 
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Table 2: Composition, encapsulation efficiency (E.E.) and burst release (within 6 h) 
of biodegradable PLA and PLGA microspheres containing vapreotide pamoate. The 
processing solvent was acetic acid. 
Polymer 
type1 
Nominal drug 
loading 
(%) 
Additive2 E. E.  
 
(%) 
Peptide released
after 6 h 
(%) 
502H 5 - 70 ± 2 16 ± 2 
502H3 10 - 65 ± 5 22 ± 1 
502H3 20 - 53 ± 2 17 ± 4 
502H 10 PEG 10000 40 ± 2 33 ± 5 
502H3 10 PEG 20000 50 ± 3 32 ± 10 
502H 20 PEG 20000 40 ± 2 30 ± 2 
502H 30 PEG 20000 38 ± 2 30 ± 2 
502H 10 BSA 38 ± 6 16 ± 2 
502H 10 Chitosan 40 ± 5 8 ± 4 
502H 10 Ethyl stearate 34 ± 5 12 ± 2 
502 10 PEG 20000 33 ± 3 29 ± 5 
752 10 - 75 ± 9 17 ± 4 
2023 10 - 73 ± 10 11 ± 3 
 
1 502H, 502, 752 and 202 refer to end-group uncapped and capped PLGA 50:50, 
end-group capped PLGA 75:25 and PLA, respectively. 
2  The nominal amount of co-encapsulated additive was generally 10%, relative to the 
PLA/PLGA-mass, except for ethyl stearate (5%). 
3 Formulations selected for in vivo study. 
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